Profile
PALI VRTX REGN VRNA ARGX ALNY
Company Name Palisade Bio, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $247.35M $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.01K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO J. D. Finley Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
PALI VRTX REGN VRNA ARGX ALNY
Quant Rating Score 2 4 4 1 4 3
Quant Rating Sell Buy Buy Strong Sell Buy Neutral
Trading
PALI VRTX REGN VRNA ARGX ALNY
Last Close $2.07 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $2.46 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.54 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -15.85 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 283.33 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
PALI VRTX REGN VRNA ARGX ALNY
1 Month Return 18.97 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return 158.43 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 201.4 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 112.53 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 25.45 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return -14.81 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
PALI VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
PALI VRTX REGN VRNA ARGX ALNY
Asset Growth -22.57 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth -100 % 1.16 % - 26.81 %
Revenue Growth -100 % 0.99 % - 22.97 %
Revenue 3 Year - 20.64 % -15.89 % 147.1 %
Revenue 5 Year -100 % 73.64 % - 775.72 %
Revenue 10 Year -100 % 285.02 % - 2487.4 %
EBIT Growth -17.43 % 9.09 % -131.37 % 24.59 %
Net Income Growth -17.38 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share 99.52 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share 85.06 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share 95.47 % 680.22 % -35.51 % 55.09 %
Operating Income Growth -13.69 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) -9.52 % - -143.33 % -107.98 %
Operating 3 Year CFG 99.28 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG 85.47 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG 92.61 % -100 % 40.15 % 97.08 %
EPS Growth 62.27 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth 62.27 % 8.19 % -208.93 % 38.07 %
Book Value Per Share -78.67 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share -99.11 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share -87.36 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share -97 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth -54.2 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth -9.48 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
PALI VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -160.99 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -240.71 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -327.81 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 100 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 97.98 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -4779.15 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM - 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -1.35 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -1.35 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 69.94 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -4779.15 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -24.53 36.72 20 -995.27 127.92 195.85
Price To Operating Cash Flows Ratio TTM -1.23 32.86 16.23 -126.33 144.41 162.25
Price Cash Flow Ratio TTM -1.23 32.86 16.23 -126.33 144.41 162.25
Income Statement (TTM)
PALI VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.34B $0.03B $2.19B $2.25B
Gross Profit $0B $9.49B $12.24B $0.03B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 85.35% 93.89% 89.62% 85.62%
EBITDA $-0.01B $0.49B $5.82B $-0.12B $0.11B $-0.18B
Net Income $-0.01B $-0.54B $4.5B $-0.14B $0.83B $-0.28B
EPS Diluted -10.19 -2.08 41.48 -1.73 12.78 -2.18
Balance Sheet (MRQ)
PALI VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.71B $0.12B $0.03B $2.59B
Total Liabilities $0B $6.12B $9.3B $0.27B $0.7B $4.17B
Total Equity $0.01B $16.41B $31.26B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $16.08B $0.02B $1.93B $1.73B
Total Debt $0B $1.75B $2.71B $0.12B $0.04B $2.74B
Total Assets $0.01B $22.53B $40.56B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
PALI VRTX REGN VRNA ARGX ALNY
Net Income $-0.01B $-0.54B $4.5B $-0.17B $0.83B $-0.28B
Inventory $0B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.98B $-0.12B $-0.08B $-0.01B
Capital Expenditure $0B $-0.3B $-0.9B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.52
AARD Aardvark Therapeutics, Inc. Common Stock 13.425
ABCL AbCellera Biologics Inc. 3.22
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.135
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.475
ABPWW 0.0155
ABSI Absci Corporation 2.76
ABUS Arbutus Biopharma Corporation 4.055
ABVC ABVC BioPharma, Inc. 1.74
ABVX Abivax SA American Depositary Shares 119.9
ACAD ACADIA Pharmaceuticals Inc. 23.225
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.12
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.1
ETFs With Exposure to PALI
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 151.98
VXF Vanguard Extended Market Index Fund 0.00394 219.57
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00394 165.43
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00394 165.44
VEMPX Vanguard Extended Market Index InstlPlus 0.00394 408.25
Unlock